Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Por:
Ribera, J, Granada, I, Morgades, M, Gonzalez, T, Ciudad, J, Such, E, Calasanz, MJ, Mercadal, S, Coll, R, Gonzalez-Campos, J, Tormo, M, Garcia-Cadenas, I, Gil, C, Cervera, M, Barba, P, Costa, D, Ayala, R, Bermudez, A, Orfao, A, Ribera, JM
Publicada:
1 feb 2022
Ahead of Print:
1 sep 2021
Resumen:
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBXI) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBXI showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBXI had a significantly higher cumulative incidence of relapse, especially among patients aged >= 35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
Filiaciones:
Ribera, J:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Carretera Canyet S-N,Cami Escoles S-N, Badalona 08916, Spain
Granada, I:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Carretera Canyet S-N,Cami Escoles S-N, Badalona 08916, Spain
Morgades, M:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Carretera Canyet S-N,Cami Escoles S-N, Badalona 08916, Spain
Gonzalez, T:
Univ Salamanca, Hosp Univ Salamanca, IBMCC, CSIC,USAL,IBSAL, Salamanca, Spain
CIBERONC, Salamanca, Spain
Ciudad, J:
Univ Salamanca, Cytometry Serv NUCLEUS, Canc Res Ctr IBMCC CSIC, USAL IBSAL, Salamanca, Spain
Univ Salamanca, Dept Med, Canc Res Ctr IBMCC CSIC, USAL IBSAL, Salamanca, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBER ONC CB16 12 0040, Madrid, Spain
Such, E:
Hosp Univ Politecn La Fe, Hematol Dept, Valencia, Spain
Calasanz, MJ:
Univ Navarra, Ctr Invest Clin Aplicada CIMA, Pamplona, Spain
Mercadal, S:
Hosp Duran & Reynals, Hematol Dept, Lhospitalet De Llobregat, Spain
Coll, R:
ICO Hosp Josep Trueta, Hematol Dept, Girona, Spain
Gonzalez-Campos, J:
Hosp Univ Virgen del Rocio, Hematol Dept, Seville, Spain
Tormo, M:
Hosp Clin Univ, Hematol Dept, Valencia, Spain
Garcia-Cadenas, I:
Hosp Santa Creu & Sant Pau, Hematol Dept, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Gil, C:
Hosp Gen Alicante, Hematol Dept, Alicante, Spain
Cervera, M:
ICO Hosp Joan XXIII, Hematol Dept, Tarragona, Spain
Barba, P:
Hosp Univ Vall dHebron, Hematol Dept, Barcelona, Spain
Costa, D:
Hosp Clin Barcelona, Dept Pathol, Haematopathol Sect, Barcelona, Spain
Ayala, R:
Hosp Univ Doce Octubre, Hematol Dept, Madrid, Spain
Bermudez, A:
Hosp Univ Marques de Valdecilla, Hematol Dept, Santander, Spain
Orfao, A:
Univ Salamanca, Cytometry Serv NUCLEUS, Canc Res Ctr IBMCC CSIC, USAL IBSAL, Salamanca, Spain
Univ Salamanca, Dept Med, Canc Res Ctr IBMCC CSIC, USAL IBSAL, Salamanca, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBER ONC CB16 12 0040, Madrid, Spain
Ribera, JM:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Carretera Canyet S-N,Cami Escoles S-N, Badalona 08916, Spain
Green Published, hybrid
|